MMRC Horizon One Adaptive Platform Trial for Evaluating Treatments in Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of multiple myeloma that has come back or is not responding to previous treatments.
• Must have tried treatments that include a proteasome inhibitor, an immunomodulating agent, and a CD38-monoclonal antibody.
• Have measurable disease, such as specific levels of M-protein or other markers in blood or urine tests.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate organ function based on specific blood test results.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during the study and for 90 days after the last treatment.
• Men must agree to use effective birth control during the study and for 90 days after the last treatment.
• Must not have severe heart disease or other conditions that would make participation unsafe.
• Must be willing and able to follow the study requirements.

Exclusion Criteria

• Have a different type of cancer that could interfere with the study.
• Have active infections or other serious medical conditions.
• Have a history of severe allergic reactions to any of the study treatments.
• Have complete spinal cord compression or cancer that has spread to the brain.
• Have received a transplant and require high doses of steroids.
• Have a psychiatric or substance abuse disorder that would interfere with participation.
• Are pregnant or breastfeeding.